figshare
Browse
pntd.0006440.g002.tif (1.42 MB)

Comparison of prescribing restrictions for primaquine and tafenoquine under three different scenarios broken down by gender.

Download (1.42 MB)
figure
posted on 2018-04-20, 17:33 authored by James Watson, Walter R. J. Taylor, Germana Bancone, Cindy S. Chu, Podjanee Jittamala, Nicholas J. White

This assumes that 10% of heterozygous females would test deficient at screens with a 30% activity threshold, and 70% of heterozygous females and 5% of all wild type individuals at a 70% threshold. Top left: current proportions of individuals ineligible for radical cure for vivax malaria following G6PD deficiency testing; top right: proportions of individuals ineligible for radical cure if primaquine and tafenoquine could be given to females breast-feeding infants older than 1 month; bottom left: proportions of individuals ineligible for radical cure if primaquine could be given to G6PD deficient persons.

History